Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13425471 | 0.88 | RAF1 (0.65) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14467713 | 0.84 | RAF1 (0.60) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL667203 | 0.84 | RAF1 (0.61) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10220677 | 0.82 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3213560 | 0.81 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10265419 | 0.81 | RAF1 (0.57) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL161668 | 0.80 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3229460 | 0.80 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3226722 | 0.80 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14726870 | 0.80 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885MAPK14 239/4885MAPK13 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.